RE: Pfizer/Seagen13 Mar 2023 22:32
Given the track record of financial management and tailoring work to fit the funds available, I would think they know exactly how further money needs will be addressed. Whatever made Redmile invest in a tiny bio on the far side of the world from them has now grown into a series of trials, further science, and of course the first licensing deal. The investment case grows stronger, but also worth wondering (among other possibilities) at what point the first stage payment might come from Genmab, and how much might that be for?